Trastuzumab rezetecan showed “clinically meaningful activity” in patients who had received previous treatment for HER2-mutated non–small cell lung cancer (NSCLC), according to recent findings from the phase 2 HORIZON-Lung trial. Ziming Li, MD, of the Shanghai Lung Cancer Center, the Shanghai Chest Hospital, and Shanghai Jiao Tong University School of Medicine, and colleagues conducted the study and published their findings in The Lancet Oncology. ...
Advertisement
Mara B. Antonoff, MD, FACS, discusses the organization's mission, the resources it offers, and her hopes for the future.
Learn how researchers determined the best treatment strategy for smoking cessation among patients who currently smoke.
The majority of symptoms at baseline consisted of pain, dyspnea, and fatigue.
The study investigators concluded that ivonescimab “might represent another treatment option in the first-line setting."
Dr. Liu unpacks key questions in the field, and the research that could address them.
Certain surgical procedures and margins were more frequent in patients who had suture-line recurrences.
The long-term follow-up data shows that PFS remains unreached in the subgroup of Asian patients in the CROWN study.
Researchers evaluated if there was a link between pretreatment systemic immune inflammation index levels and outcomes.
Study investigators say the combination "showed promising efficacy" in patients with relapsed small cell lung cancer.
Clinicians hypothesize that the genetic mutation, known as RUFY1-RET fusion, caused resistance to lorlatinib.
Roundtable Discussions
Expert Interviews
Conference Coverage
Find key news in thoracic oncology from the 61st Annual Meeting of the Society of Thoracic Surgeons.
Find the latest news and updates on lung cancer from the ESMO Congress 2024.
Find the latest updates on lung cancer treatment and research from the IASLC 2024 World Conference on Lung Cancer.
Find the latest updates on lung cancer treatment and research from the 2024 ASCO Annual Meeting.
Our editors detail the latest data and innovations in the lung cancer space presented at ATS 2024.
Our editors provide coverage on the development of innovative cancer therapeutics, as presented at ESMO TAT 2024.
Our editors deliver in-depth coverage of NACLC 2023, a premier event offering the latest data on lung cancer advancements.
Our editors provide comprehensive coverage of ESMO Congress 2023, with a focus on lung cancer.
Our editors detail the latest data and innovations in the lung cancer space, as presented at WCLC 2023.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.